GSK’s majority-owned HIV unit ViiV has agreed licensing deals ... HIV integrase inhibitor is one of ViiV’s most up-to-date products, only getting FDA approval under the Apretude brand name ...

Three years after the discovery of the human immunodeficiency virus (HIV) in 1984, GlaxoSmithKline's (GSK's) Retrovir (zidovudine) became the first drug to be approved for the treatment of this ...

The turnaround will help to alleviate fears about GSK’s ability to handle the loss of patent protection to key HIV therapy dolutegravir from 2028 onwards, starting in the US. Products containing ...

People living with HIV and people with potential exposure to HIV in China are expected to leverage more of GlaxoSmithKline's innovative research results for the prevention and treatment of the ...

GSK plc GSK boasts a diversified ... Ojjaara and Jemperli and new long-acting HIV medicines, Cabenuva and Apretude. These new ...

“We have strengthened capabilities in key technology platforms and completed investments to develop new mRNA vaccines, ...

GSK lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher. The British pharmaceutical firm said sales ...

The short answer is yes. GSK has continued to beat my expectations as well as analysts' expectations in recent quarters, thanks to solid sales of its HIV and oncology franchises. Not only has the ...

Focusing on the present, three of the firm’s top selling products are Menveo and ... disease treatment called Nucala and HIV medicine called Cavenuva. GSK plc (NYSE:GSK)’s management provided ...

GSK, the London-listed pharmaceutical giant, has upgraded its guidance following a robust second quarter that surpassed market predictions, driven by its cancer and HIV portfolio ... include at least ...

Tuesday’s FTC letter to GSK also related to asthma and lung disease products ... thanks to strong sales of its shingles vaccine and HIV drugs, boosting total sales by 10 per cent in the ...

Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against medical spas, wellness clinics, and compounding pharmacies for allegedly selling products ...